Blueprint welcomes new investors!

Published on July 11, 2017

We are extremely happy to welcome two new investors on board Blueprint Genetics. Our new partners are Creathor, a venture fund based in Germany, and MTIP (MedTech Innovation Partners), a venture fund based in Switzerland. Our existing investors are also participating in the funding round that totals €14m.

As a result, our total funding to date will be €23m. Last time we announced funding news was in September 2014, but during 2015 and 2016 we have had the privilege of raising €6m in several tranches from our existing investors, who include Pontos, Inventure and Avohoidon Tutkimussäätiö.

The new funding strengthens our position significantly. It enables us to expand our footprint in both existing and new markets, and enables us to invest in our clinical interpretation capabilities, artificial intelligence initiatives and technology platform overall. In addition to growth and R&D, we are able to add new resources across the board into our organization, helping us serve our existing and new customers better than ever.


The announcement is available on the Creathor website.


On the behalf of the entire Blueprint team – Welcome Creathor and MTIP!


Creathor Venture     MTIP MedTech Innovation Partners AG

Last modified: 07.11.2017


Blueprint Genetics expands capabilities in the detection and confirmation of difficult-to-sequence regions

Published on October 17, 2018

The latest advancement in Blueprint Genetics’ production environment involves customized sequencing solutions for difficult-to-sequence genes, designed to maximize detection of clinically relevant variants. Currently, the most extensive developments are in genes SMN1/SMN2, PKD1 and RPGR (ORF15), associated with spinal muscular atrophy, autosomal dominant polycystic kidney disease and X-linked retinitis pigmentosa,…

Read more

Subscribe to our newsletter